Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Assets (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Assets data on record, last reported at $332.6 million in Q4 2025.

  • For Q4 2025, Assets rose 71.79% year-over-year to $332.6 million; the TTM value through Dec 2025 reached $332.6 million, up 71.79%, while the annual FY2025 figure was $332.6 million, 71.79% up from the prior year.
  • Assets reached $332.6 million in Q4 2025 per AMLX's latest filing, down from $362.7 million in the prior quarter.
  • Across five years, Assets topped out at $517.5 million in Q4 2023 and bottomed at $105.6 million in Q4 2021.
  • Average Assets over 5 years is $313.4 million, with a median of $332.2 million recorded in 2024.
  • Peak YoY movement for Assets: soared 270.64% in 2022, then crashed 62.58% in 2024.
  • A 5-year view of Assets shows it stood at $105.6 million in 2021, then skyrocketed by 270.64% to $391.5 million in 2022, then skyrocketed by 32.19% to $517.5 million in 2023, then plummeted by 62.58% to $193.6 million in 2024, then soared by 71.79% to $332.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $332.6 million in Q4 2025, $362.7 million in Q3 2025, and $194.6 million in Q2 2025.